Robert Spurr, CEO and President of LEO Pharma Inc., discusses the U.S. Food and Drug Administration’s recent nod for delgocitinib cream (Anzupgo) in chronic hand eczema and what this new treatment option means for patients and healthcare providers. Read the full story here.
